Hematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationGraft vs Host DiseaseTransplantation ConditioningBone Marrow TransplantationTissue DonorsBone MarrowTransplantation, AutologousBone Marrow CellsHematologic NeoplasmsPeripheral Blood Stem Cell TransplantationTransplantation ChimeraStem CellsGraft SurvivalHistocompatibility TestingBusulfanTreatment OutcomeGraft vs Leukemia EffectHematopoietic Stem CellsMyeloablative AgonistsRemission InductionVidarabineRecurrenceGraft vs Tumor EffectWhole-Body IrradiationHematopoietic Stem Cell MobilizationLeukemiaLymphocyte TransfusionCord Blood Stem Cell TransplantationLeukemia, Myeloid, AcuteImmunosuppressive AgentsMultiple MyelomaBone and BonesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveRetrospective StudiesHistocompatibilityCombined Modality TherapyT-LymphocytesLymphocyte DepletionCytomegalovirus InfectionsMyelodysplastic SyndromesSiblingsLiver TransplantationMinor Histocompatibility AntigensGranulocyte Colony-Stimulating FactorSurvival AnalysisDisease-Free SurvivalSalvage TherapyChimerismPrecursor Cell Lymphoblastic Leukemia-LymphomaTime FactorsLiving DonorsAntilymphocyte SerumSurvival RateNeoplasm, ResidualAntigens, CD34Blood DonorsMesenchymal Stem Cell TransplantationAnemia, AplasticVirus ActivationMelphalanCyclophosphamideDonor SelectionCell TransplantationHepatic Veno-Occlusive DiseaseCells, CulturedAntineoplastic Combined Chemotherapy ProtocolsAcute DiseaseCell DifferentiationHLA AntigensPrimary MyelofibrosisCytomegalovirusTransplantation ImmunologyKidney TransplantationHematologic DiseasesImmunosuppressionFlow CytometryGraft RejectionMice, Inbred C57BLFollow-Up StudiesHematopoiesisLeukemia, MyeloidEmbryonic Stem CellsPrognosisCytarabineLeukemia, Myeloid, Accelerated PhaseTransplantation, IsogeneicBone Marrow DiseasesLeukocyte TransfusionSpleenAntibodies, NeoplasmAdult Stem CellsAntineoplastic AgentsLymphoproliferative DisordersLymphocytesImmunocompromised HostRoseolovirus InfectionsBenzamidesMesenchymal Stromal Cells